MANNKIND
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product candidate, AFREZZA(R), is in the late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. It maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind.
MANNKIND
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2001-01-01
Address:
Valencia, California, United States
Country:
United States
Website Url:
http://www.mannkindcorp.com
Total Employee:
501+
Status:
Active
Contact:
(661)775-5300
Total Funding:
360 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Google Tag Manager WordPress Font Awesome Domain Not Resolving Nginx
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Aprea
Aprea is a biopharmaceutical company that develops novel cancer therapeutics.
Arvinas
Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Radius Health
Radius Health develops drug therapies for osteoporosis and women’s health.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Deerfield Capital Management
Deerfield Capital Management investment in Post-IPO Debt - MannKind
Deerfield
Deerfield investment in Post-IPO Debt - MannKind
Official Site Inspections
http://www.mannkindcorp.com Semrush global rank: 2.38 M Semrush visits lastest month: 7.72 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "MannKind"
MannKind Corporation - Life more humann
Drawing on the legacy of innovator and humanitarian Alfred E. Mann, our team of passionate scientists, researchers, and professionals develops cutting-edge therapeutic products and …See details»
Corporate Governance - MannKind Corporation
Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the …See details»
About MannKind's Mission - Our Corporation's Legacy & Values
How MannKind is changing lives for the better. Drawing on the legacy of innovator and humanitarian Alfred E. Mann, we aim to develop therapeutic products and devices that can …See details»
MannKind Corporation - Wikipedia
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991. MannKind Corporation was named after its founder, Alfred E. Mann. See details»
Investor Home - MannKind Corporation
Nov 7, 2024 · MannKind Corporation is focused on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those …See details»
MannKind Corporation - LinkedIn
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with...See details»
MannKind Corporation - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for MannKind Corporation of Danbury, CT. Get the latest business insights from Dun & Bradstreet.See details»
MannKind Website - Homepage
Make a humann connection with us. Reach out anytime. contact. Terms of Use; Privacy Policy; Patent Notices; Corporate GovernanceSee details»
Lauren Sabella Joins Mannkind as Executive Vice President, Chief ...
Mar 27, 2023 · MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet …See details»
MannKind Corporation (MNKD) Company Profile & Facts - Yahoo …
See the company profile for MannKind Corporation (MNKD) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Clinical Trials - MannKind Corporation
Check out our research and development pipeline focused on endocrine and orphan lung diseases. See how our technologies and therapies can help more people take control of their health.See details»
MannKind Corporation - BioCT
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those …See details»
MannKind - Crunchbase Company Profile & Funding
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead …See details»
Careers - MannKind Corporation
MannKind Corporation is looking for people who are driven to find new ways of changing lives for the better. Our team is energized by the company’s entrepreneurial spirit that provides an …See details»
MannKind Corporation - Company Profile & Staff Directory
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those …See details»
Steven Binder Joins MannKind as Chief Financial Officer
VALENCIA, Calif., July 17, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today announced that Steven Binder has joined the …See details»
MannKind Corporation Reports 2022 Fourth Quarter and Full Year ...
“For 2022, we recognized almost $100 million in total revenues – an incredible triumph for our entire organization,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind …See details»
Pipeline - MannKind Corporation
MannKind's pipeline and collaborations to develop and advance new products and help people take control of their health. Explore our pipeline and collaborations.See details»
MannKind Corporation - Facebook
MannKind Corporation. 1,459 likes · 40 talking about this. MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of...See details»
MannKind Corporation Reports 2021 Fourth Quarter and Full Year ...
Feb 24, 2022 · Simply put, the lungs create a wonderful platform for effective drug delivery. MannKind’s Technosphere technology recognizes this and provides the distinct advantage of …See details»